| The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer JL Low, RJ Walsh, Y Ang, G Chan, RA Soo Therapeutic advances in medical oncology 11, 1758835919870360, 2019 | 66 | 2019 |
| Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer JL Low, Y Huang, K Sooi, Y Ang, ZY Chan, K Spencer, AD Jeyasekharan, ... International Journal of Cancer 149 (1), 169-176, 2021 | 33 | 2021 |
| Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: experience from a single Asian centre GHJ Chan, YX Gwee, JL Low, Y Huang, ZY Chan, JRE Choo, NYL Ngoi, ... Lung Cancer 146, 145-153, 2020 | 22 | 2020 |
| Different treatment efficacies and side effects of cytotoxic chemotherapy LJ Li, Q Chong, L Wang, GB Cher, RA Soo Journal of Thoracic Disease 12 (7), 3785, 2020 | 21 | 2020 |
| Vitamin D binding protein and vitamin D levels in multi-ethnic population RA Merchant, RM van Dam, LWL Tan, MY Lim, JL Low, JE Morley The Journal of nutrition, health and aging 22 (9), 1060-1065, 2018 | 19 | 2018 |
| Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations JL Low, SM Lim, JB Lee, BC Cho, RA Soo Therapeutic Advances in Medical Oncology 15, 17588359221146131, 2023 | 17 | 2023 |
| Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer Y Huang, JJ Zhao, YY Soon, A Wong, F Aminkeng, Y Ang, Y Asokumaran, ... Thoracic Cancer 13 (22), 3152-3161, 2022 | 17 | 2022 |
| Low-dose nivolumab in renal cell carcinoma: a real-world experience JJ Zhao, NB Kumarakulasinghe, V Muthu, M Lee, R Walsh, JL Low, ... Oncology 99 (3), 192-202, 2021 | 14 | 2021 |
| Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia JL Low, E Lim, L Bharwani, A Wong, K Wong, S Ow, SE Lim, M Lee, ... Therapeutic Advances in Medical Oncology 14, 17588359221139678, 2022 | 13 | 2022 |
| Atypical response patterns in renal cell carcinoma treated with immune checkpoint inhibitors—navigating the radiologic potpourri A Wong, B Vellayappan, L Cheng, JJ Zhao, V Muthu, Y Asokumaran, ... Cancers 13 (7), 1689, 2021 | 12 | 2021 |
| Management of HER2 alterations in non-small cell lung cancer–the past, present, and future J Nützinger, JB Lee, JL Low, PL Chia, ST Wijaya, BC Cho, SM Lim, ... Lung Cancer 186, 107385, 2023 | 11 | 2023 |
| Use of the Cancer and Aging Research Group Predictive Model for Chemotherapy-Related Toxic Effects in a Multiethnic, Older Adult Asian Population A Pang, L Jiali, A Ng, J Cheng, M Wang, YS Ng, Y Yao, M Chun, F Ho, ... JAMA Network Open 5 (10), e2237196-e2237196, 2022 | 5 | 2022 |
| Protocol for a systematic review with prospective individual patient data meta-analysis in EGFR-mutant NSCLC with brain metastases to assess the effect of SRS+ osimertinib … KP Robledo, S Lefresne, YY Soon, A Sahgal, MB Pinkham, A Nichol, ... BMJ open 14 (7), e078335, 2024 | 1 | 2024 |
| 794P Efficacy of gemcitabine (gem) based therapy in ovarian clear cell carcinoma (OCCC) J Loh, NYL Ngoi, F Blanc-Durand, SYR Ang, E Elias, A Lai, D Lim, ... Annals of Oncology 34, S532-S533, 2023 | 1 | 2023 |
| Management of oncogene driven locally advanced unresectable non-small cell lung cancer J Loh, JL Low, M Sachdeva, PQJ Low, RSJ Wong, Y Huang, PL Chia, ... Expert Review of Anticancer Therapy 23 (9), 913-926, 2023 | 1 | 2023 |
| P. 134 Real-world outcomes of exon skipping therapy use in patients with Duchenne muscular dystrophy: Experience at a single, large tertiary care center A Yaworski, T Duong, J Low, R Gee, K Watson, M Buu, B Kaufman, J Klotz, ... Neuromuscular Disorders 32, S102, 2022 | 1 | 2022 |
| Improving the uptake of prehabilitation interventions for older adults prior to cancer treatment using telehealth in the Geriatric Oncology One-Stop Clinic. YS Ng, NM Said, MZ Chen, WN Eng, NMW Ling, JL Low, Y Yao, Y Loy, ... Journal of Clinical Oncology 40 (28_suppl), 55-55, 2022 | 1 | 2022 |
| Pan-immune-inflammation value as a predictive biomarker for survival in advanced non-small cell lung cancer patients treated with immunotherapy. K Sooi, JL Low, QH Miow, NB Kumarakulasinghe, R Sundar, Y Huang Journal of Clinical Oncology 40 (16_suppl), e21095-e21095, 2022 | 1 | 2022 |
| Cost and efficacy of low-dose pembrolizumab in the treatment of non-small cell lung cancer patients in Asia. JL Low, K Sooi, Y Huang, GHJ Chan, Y Ang, WQ Chong, HL Tan, N Ngoi, ... Journal of Clinical Oncology 38 (15_suppl), e19385-e19385, 2020 | 1 | 2020 |
| Phase I study of low dose whole abdominal radiation therapy (LDWART) in combination with weekly paclitaxel (wP) for platinum resistant ovarian cancer (PROC) NYL Ngoi, VYM Heong, NB Kumarakulasinghe, PS Phyu, EY Peh, SE Lim, ... Annals of Oncology 30, v422, 2019 | 1 | 2019 |
